CORDIS
EU research results

CORDIS

English EN
Evidence-based probiotic for Chronic Fatigue Syndrome

Evidence-based probiotic for Chronic Fatigue Syndrome

Objective

Let’s imagine being tired to the point where any activity causes weeks of weakness and pain. Common noises and daylight become an unbearable torture and a “brain fog” doesn’t let you think clearly. In spite of the tiredness, you wake up without being refreshed, if you can fall asleep at all. Days pass as well as doctors check-ups, and no one is able to tell you what is wrong. Finally, after few years of trying to pull yourself up, the answer is Chronic Fatigue Syndrome (CFS). Happy of the fact of being diagnosed, you quickly learn that it means that there are no measures able to cure you and chances of full recovery are only 5%.
Indeed, the reality of CFS patients’ life is tough and contrary to many beliefs it is not a rare disease. The world count of diagnosed CFS is estimated for up to 24 million cases and considered to be only 10% of the whole CFS population. Although frequently triggered by infection, cause of CFS is not yet known. Researches look for its source in the guts, which are inhabited by billions of microorganisms and form a complex ecosystem with profound impact on the whole body. Imbalance of gut microflora, damaged gut barrier functions and dysfunctional immune responses are known in CFS and shared with another disease - Irritable Bowel Syndrome (IBS), which frequently accompany CFS.
GutMagnific™ is an evidence-based probiotic scientifically designed and shown to be effective in correcting the gut microflora disbalance – a source of CFS and IBS symptoms. The novelty of the product lies in the unique combination of 5 lactobacilli strains with evidence-based efficacy and shows a life-changing promise to severely underserved population of CFS patients.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

IMMUNEBIOTECH MEDICAL SWEDEN AB

Address

Korsakersvagen 53
226 50 Lund

Sweden

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

EU Contribution

€ 50 000

Project information

Grant agreement ID: 867223

Status

Ongoing project

  • Start date

    1 April 2019

  • End date

    30 September 2019

Funded under:

H2020-EU.3.

H2020-EU.2.3.

H2020-EU.2.1.

  • Overall budget:

    € 71 429

  • EU contribution

    € 50 000

Coordinated by:

IMMUNEBIOTECH MEDICAL SWEDEN AB

Sweden